Our Work
Latham & Watkins Assists Opiant Pharmaceuticals in Securing CFIUS Clearance
February 9, 2023
CFIUS concluded that there were no unresolved national security concerns with respect to Opiant’s acquisition by Indivior.
Opiant Pharmaceuticals, Inc., (NASDAQ: OPNT), a biopharmaceutical company developing treatments for addiction and drug overdose leveraging intranasal and injectable delivery technologies, has received clearance from the Committee on Foreign Investment in the United States (CFIUS) in connection with its acquisition by global pharmaceutical company Indivior. CFIUS concluded that there were no unresolved national security concerns with respect to the transaction.
Latham & Watkins LLP represented Opiant Pharmaceuticals in the CFIUS clearance process with a team led by Washington, D.C. partner Jim Barker, with associates Julie Choi Shin and Ragad Alfaraidy. The transaction is led by Chicago M&A partners Christopher Drewry and Max Schleusener.